Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
17 January 2025
Australian Medical Council accreditation update
The AMC’s response to our 2024 progress report is encouraging with 14 conditions and sub-conditions ...
10 January 2025
Update on New South Wales workforce issues
More than 200 individual senior NSW psychiatrists have resigned, citing patient safety concerns.
20 December 2024
RANZCP update on NSW workforce issues
The RANZCP has been increasingly concerned about the significant gaps in the workforce across New So...